| Literature DB >> 32582785 |
Biswajit Bhowmick1,2, Qian Han1,2.
Abstract
Ticks are obligate blood-feeding ectoparasites that transmit a wide variety of pathogens to animals and humans in many parts of the world. Currently, tick control methods primarily rely on the application of chemical acaricides, which results in the development of resistance among tick populations and environmental contamination. Therefore, an alternative tick control method, such as vaccines have been shown to be a feasible strategy that offers a sustainable, safe, effective, and environment-friendly solution. Nevertheless, novel control methods are hindered by a lack of understanding of tick biology, tick-pathogen-host interface, and identification of effective antigens in the development of vaccines. This review highlights the current knowledge and data on some of the tick-protective antigens that have been identified for the formulation of anti-tick vaccines along with the effects of these vaccines on the control of tick-borne diseases.Entities:
Keywords: Borrelia; Ixodes; anti-tick vaccines; blood; saliva; transmission-blocking
Year: 2020 PMID: 32582785 PMCID: PMC7297041 DOI: 10.3389/fvets.2020.00319
Source DB: PubMed Journal: Front Vet Sci ISSN: 2297-1769
Common tick-borne diseases and their vectors with different transmission cycles.
| Farm animal | Heartwater | 48–96 h | No | ( | ||
| Companion animal | Canine cyclic thrombocytopenia | 16–72 h | No | ( | ||
| Human and farm animal | Human granulocytic anaplasmosis, tick-borne fever | 24–48 h | No | ( | ||
| Human | Rocky Mountain spotted fever | 10 h | Yes | ( | ||
| Farm animal | Bovine anaplasmosis | 24–48 h | No | ( | ||
| Human and companion animal | Lyme disease | 16–72 h | No | ( | ||
| Human and farm animal | Crimean-Congo hemorrhagic fever | Immediate | Yes | ( | ||
| Farm animal | Louping ill | Immediate | No | ( | ||
| Human | Tick-borne encephalitis | Immediate | Yes | ( | ||
| Farm animal | Tropical theileriosis | 48 h | No | ( | ||
| Human | Human babesiosis | 48–72 h | Yes/ No | ( | ||
| Companion animal | Canine babesiosis | 48 h | Yes | ( | ||
| Farm animal | Bovine babesiosis | 48–216 h | No | ( |
Saliva-assisted transmission blocking anti-tick vaccine candidates.
| TSLPI | Tick salivary lectin pathway inhibitor | Facilitates transmission from ticks to mice and from mice to ticks | ( | ||
| tHRF | Tick histamine release factor (vasodilation) | Promotes late stage feeding and thereby facilitates tick to host transmission | ( | ||
| Salp15 | Secreted salivary protein (acquired immune responses) | Facilitates transmission from ticks to mice | ( | ||
| Salp25 D | Salivary protein, antioxidant (acquired immune responses) | Facilitates transmission from mice to ticks | ( | ||
| Salp16 | Secreted salivary protein (acquired immune responses) | Facilitates transmission from ticks to mice | ( | ||
| Subolesin (SUB) | A reduction in tick weight and/or oviposition | Tick protective antigen (innate immune response, reproduction, and development of ticks) | ( | ||
| Subolesin (SUB) | Nuclear factor kappa B (NF-kB) | Tick protective antigen (innate immune response, reproduction, and development of ticks) | ( | ||
| 64P | Dual-action (exposed and concealed) | Tick cement protein, secreted glycine-rich proteins | ( | ||
| Sialo L2 | Secreted salivary protein (acquired immune responses) | Increases level of skin infection following syringe inoculation | ( | ||
| Sialo L2 | Secreted salivary protein (acquired immune responses) | Protection by inhibiting inflammasome formation in mice | ( | ||
| Salp20 | Secreted salivary protein (acquired immune responses) | Protection by inhibiting the complement pathway | ( |
Figure 1A schematic representation of tick physiological processes and involved molecules tested as vaccine candidates [modified from (78, 103)]. The most promising vaccine candidates are underlined. The red arrow represents blood meal uptake, and the blue arrow represents saliva injection. Several tick protease inhibitor families have been reported in the salivary glands and implicated in both tick biology/physiology. Major blood digestive enzymes (cathepsin B, C, D, L, and Legumain), blood digestion, heme/iron metabolism, detoxification, and inter-tissue transport that may serve as rational targets for “anti-tick” intervention. SG, salivary glands; MG, midgut; OV, ovary; HLS2, Haemaphysalis longicornis serpin-2; RAS-1,2,3,4, Rhipicephalus appendiculatus; IRIS, Ixodes ricinus immunosuppressor; Sialostatin L, Ixodes scapularis; OmC2, Ornithodoros moubata; Metis-1, metalloproteases from Ixodes ricinus; BrRm-MP4, metalloproteases Rhipicephalus (Boophilus) microplus; HLMP1, Haemaphysalis longicornis metalloprotease.
Figure 2A proposed model for the hemoglobinolytic pathway in I. ricinus [modified from (75)]. The enzymes are color-coded according to clan membership- AA clan aspartic peptidases (red), CD clan cysteine peptidases (purple), CA clan (papain family) cysteine peptidases (green), and serine and metallopeptidases (black). The endopeptidases, cathepsin D (CatD) supported by cathepsin L (CatL) and legumain (AE), are responsible for the primary cleavage of hemoglobin. The production of secondary small fragments is dominated by the endopeptidase activity of cathepsin B (CatB). Exopeptidases act on the peptides released by the action of the endopeptidases through the carboxy-dipeptidase activity of CatB and the amino-dipeptidase activity of cathepsin C (CatC). Monopeptidases, including leucine aminopeptidase (LAP) and serine carboxypeptidase (SCP), might participate in the liberation of free amino acids.
Lists of cysteine and aspartic peptidases identified from different tick species [modified from (75)].
| Serine proteases | HlSP, HlSP2, HlSP3 | RNAi and recombinant enzymes | Midgut and midgut lumen | |
| Legumain | H1Lgm, H1Lgm2 | RNAi and recombinant enzymes | Midgut | |
| Cathepsin L | IrCL1 | RNAi and native or recombinant enzymes | Midgut, salivary glands, ovaries, and Malpighian tubules | |
| Cathepsin L | BmCL1 | Native or recombinant enzymes | Midgut | |
| Cathepsin B | Longipain | RNAi and recombinant enzymes | Midgut | |
| Cathepsin D | IrCD1 | RNAi and native or recombinant enzymes | Midgut | |
| Cathepsin D | Longepsin | RNAi and recombinant enzymes | Midgut and salivary glands | |
| Leucine amidopeptidase | HlLAP | RNAi and recombinant enzymes | Midgut, salivary glands, ovaries, and epidermis | |
| Legumain | IrAE | RNAi and native or recombinant enzymes | Midgut | |
| Cathepsin L | H1CPL-A | Recombinant enzymes | Midgut | |
| Cathepsin C | IrCC | Native enzyme | Midgut, salivary glands, ovaries, and Malpighian tubules | |
| Cathepsin B | IrCB1 | Native enzyme | Midgut | |
| Cathepsin D | BmAP | Native enzyme | Midgut |
Tick antigens developed based on biological process and vaccine approaches tested for vaccine development against ticks.
| Secreted | Putative cement protein | 64TRP | Recombinant protein, 2nd generation | 62 and 47% mortality | ( | |
| Serine protease inhibitor | RAS-3, RAS-4, RIM36 | Recombinant protein, 2nd generation | 39 and 48% mortality | ( | ||
| Cystatin type 2 | Sialostatin L2 | Recombinant protein, 2nd generation | 40% mortality | ( | ||
| Cystatin type 2 | Sialostatin L | Recombinant protein, 2nd generation | Not reported | ( | ||
| Serine protease inhibitor | IRIS | Recombinant protein, 2nd generation | 30% mortality | ( | ||
| Ferritin, iron transporter | RaFER2/RmFER2 | Recombinant protein, 2nd generation | 64 and 72% efficacy | ( | ||
| Membrane associated | Angiotensin converting enzyme | Bm91 | Recombinant protein, 2nd generation | 6% reduction of reproductive index | ( | |
| Aquaporin | Aquaporin | Reverse vaccinology, 3rd generation | 75 and 68% efficacy | ( | ||
| Bm86 and orthologs | Bm86 and orthologs | Recombinant protein, 2nd generation | 45–100% efficacy | ( | ||
| 5′-nucleotidase | 4F8 | Recombinant protein, 2nd generation | No efficacy | ( | ||
| Mucin | BMA7 | Purified components, 2nd generation | 21% reduction in egg weights | ( | ||
| Intracellular | Elongation factor | Ef1a | Recombinant protein, 2nd generation | 31% efficacy | ( | |
| Acidic ribosomal protein P0 | pP0 | Synthetic peptide, 2nd generation | 96% efficacy | ( | ||
| Glutathione S transferase | GST-HI | Recombinant protein, 2nd generation | 57% efficacy | ( | ||
| Regulator factor | Subolesin (4D8) | Recombinant protein, 2nd generation | 0–83% efficacy | ( | ||
| Ubiquitin | UBE | Recombinant protein, 2nd generation | 15 and 55% efficacy | ( |
Figure 3A schematic representation of the integrative reverse vaccinology approach toward vaccine development.